Ipamorelin dosing used in clinical trials: 0.03 mg/kg (30 mcg/kg) twice daily in some studies
This would define the healing in the other tissues, that is, gastrointestinal tract, tendon, ligament, muscle, bone, nerve, spinal cord, cornea (maintained transparency), and blood vessels, seen with BPC 157 therapy
Pearls and Quotes GLP-1 Agonists: Mechanisms to Applications The selection and dosing of GLP-1 and GIP agonists (GLP-1s and GIPs) depends on their intended use as an anti-glycemic or anti-obesity agent
R.KorolainenM
JOE ROGAN: Was Fauci running the NIH back then
Tirzepatide combines the incretin effects of GLP-1 with GIP, the latter of which contributes to appetite regulation and further reductions in food intake